Advertisement
BDX vs COO
Which Stock Would AI Choose? Becton, Dickinson and Company (BDX) vs. The Cooper Companies, Inc. (COO) Stock Comparison
Key Takeaways
- Becton, Dickinson and Company (BDX) and The Cooper Companies, Inc. (COO) both operate in the medical devices sector but differ in scale, with BDX holding a larger market capitalization of approximately $40.5 billion compared to COO’s roughly $11.9 billion.
- Recent market activity shows BDX experiencing modest declines amid broader sector pressures, while COO has shown relative resilience in price performance over the past month.
- BDX recently reported second-quarter fiscal 2026 results that beat estimates and prompted an upward revision to full-year adjusted earnings per share guidance, driven by strong demand in drug delivery devices.
- COO is scheduled to release its second-quarter fiscal 2026 results on June 4, 2026, following first-quarter revenue growth of 6% (3% organic) and an upgraded full-year revenue outlook.
- Both companies maintain exposure to healthcare end-markets, yet BDX benefits from a broader product portfolio including surgical and interventional solutions, whereas COO focuses more narrowly on contact lenses via CooperVision and women’s health via CooperSurgical.
- Market sentiment reflects BDX’s portfolio refocusing after a recent business separation, contrasted with COO’s emphasis on premium product ramps and long-term free cash flow targets.
Introduction
This comparison examines Becton, Dickinson and Company (BDX) and The Cooper Companies, Inc. (COO), two healthcare-focused medical device companies, to highlight differences in business models, recent financial results, and market positioning. Institutional investors, active traders, and portfolio managers evaluating relative value within the medical instruments and supplies industry may find this analysis relevant for assessing sector exposure, growth drivers, and risk profiles in the current environment.
BDX Overview and Recent Performance
Becton, Dickinson and Company (BDX) develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. In recent weeks, the stock has traded near $147 amid modest downward pressure, reflecting broader market dynamics in healthcare. Recent market activity includes the company’s second-quarter fiscal 2026 earnings release in early May, which featured revenue of $4.7 billion (up 5.2% reported) and an adjusted diluted earnings per share beat that led to a raised full-year guidance range. The performance was supported by demand in drug delivery devices following the separation of its biosciences and diagnostic solutions businesses earlier in the year. Sentiment has been influenced by these portfolio adjustments and leadership updates, contributing to a focus on core medical and interventional segments.
COO Overview and Recent Performance
The Cooper Companies, Inc. (COO) develops, manufactures, and markets contact lenses through its CooperVision segment and products for women’s and family health through CooperSurgical. In recent weeks, the stock has hovered around $61 with relatively stable trading patterns. Recent market activity centers on the upcoming second-quarter fiscal 2026 earnings release scheduled for June 4, following first-quarter results that showed revenue of $1.024 billion (up 6%, or 3% organically). The company previously raised its full-year 2026 revenue guidance, underscoring expectations for continued organic growth. Performance has been shaped by efforts to expand premium lens offerings and fertility-related products, with management highlighting progress toward multi-year free cash flow objectives.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots drawn from hundreds available on the platform that collectively trade thousands of different tickers. Only those demonstrating strong suitability for prevailing market conditions earn placement in this section. The bots encompass a wide range of trading styles, strategies, timeframes, performance metrics, and ticker sets, enabling users to explore options aligned with specific objectives. Factual statistics on the platform include varied historical win rates, average returns, and drawdown profiles across the full suite. This resource provides traders with transparent data to evaluate automated strategies. Explore the Trending AI Robots page for additional details.
Head-to-Head Comparison
Becton, Dickinson and Company (BDX) maintains a diversified business model spanning medical essentials, interventional procedures, and related segments, offering broader sector exposure than The Cooper Companies, Inc. (COO), which concentrates on vision care and surgical products for women’s health. Growth drivers for BDX include demand for drug delivery solutions and post-separation operational focus, while COO emphasizes premium contact lens adoption and fertility services. Recent momentum has favored BDX following its earnings beat and guidance increase, whereas COO’s positioning reflects anticipation around its forthcoming results and prior organic growth achievements. Risk factors for BDX involve integration of its refocused portfolio and macroeconomic pressures on healthcare spending; for COO, these include competition in the contact lens market and execution on product ramps. Market sentiment appears constructive for both given their healthcare defensiveness, yet trade-offs exist in scale, dividend policy (BDX offers a yield while COO does not), and valuation multiples.
Tickeron AI Verdict
Based on observable factors such as recent earnings consistency, guidance momentum, and relative stability in trend signals, Tickeron’s AI would likely assign a modest probabilistic edge to Becton, Dickinson and Company (BDX) in the current environment. The company’s demonstrated ability to exceed expectations and adjust forward targets provides a clearer catalyst profile compared with The Cooper Companies, Inc. (COO)’s pre-earnings positioning. This assessment remains probabilistic and tied to ongoing market data rather than a definitive recommendation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDX is a StrongBuy and COO is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 1 FA rating(s) are green whileCOO’s FA Score has 1 green FA rating(s).
- BDX’s FA Score: 1 green, 4 red.
- COO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 4 TA indicator(s) are bullish while COO’s TA Score has 6 bullish TA indicator(s).
- BDX’s TA Score: 4 bullish, 6 bearish.
- COO’s TA Score: 6 bullish, 4 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а -2.57% price change this week, while COO (@Pharmaceuticals: Other) price change was +0.80% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.49%. For the same industry, the average monthly price growth was +1.13%, and the average quarterly price growth was -15.35%.
Reported Earning Dates
BDX is expected to report earnings on Jul 30, 2026.
COO is expected to report earnings on Sep 02, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-0.49% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BDX | COO | BDX / COO | |
| Capitalization | 40.3B | 13.2B | 305% |
| EBITDA | 4.97B | 1.08B | 458% |
| Gain YTD | -2.886 | -17.179 | 17% |
| P/E Ratio | 25.52 | 57.53 | 44% |
| Revenue | 22.2B | 4.15B | 535% |
| Total Cash | N/A | 125M | - |
| Total Debt | 17.3B | 2.5B | 692% |
BDX | COO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 87 | 86 | |
PRICE GROWTH RATING 1..100 | 57 | 53 | |
P/E GROWTH RATING 1..100 | 76 | 15 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (5) in the Medical Specialties industry is significantly better than the same rating for COO (73). This means that BDX’s stock grew significantly faster than COO’s over the last 12 months.
BDX's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as COO (100). This means that BDX’s stock grew similarly to COO’s over the last 12 months.
COO's SMR Rating (86) in the Medical Specialties industry is in the same range as BDX (87). This means that COO’s stock grew similarly to BDX’s over the last 12 months.
COO's Price Growth Rating (53) in the Medical Specialties industry is in the same range as BDX (57). This means that COO’s stock grew similarly to BDX’s over the last 12 months.
COO's P/E Growth Rating (15) in the Medical Specialties industry is somewhat better than the same rating for BDX (76). This means that COO’s stock grew somewhat faster than BDX’s over the last 12 months.
| BDX | COO | |
|---|---|---|
| RSI ODDS (%) | 7 days ago 44% | 3 days ago 37% |
| Stochastic ODDS (%) | 3 days ago 52% | 3 days ago 61% |
| Momentum ODDS (%) | 3 days ago 49% | 3 days ago 56% |
| MACD ODDS (%) | 3 days ago 47% | 3 days ago 56% |
| TrendWeek ODDS (%) | 3 days ago 45% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 44% | 3 days ago 49% |
| Advances ODDS (%) | 10 days ago 43% | 10 days ago 57% |
| Declines ODDS (%) | 3 days ago 43% | 4 days ago 60% |
| BollingerBands ODDS (%) | 3 days ago 55% | 3 days ago 57% |
| Aroon ODDS (%) | 3 days ago 48% | 3 days ago 50% |
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | -0.75% | ||
| COO - BDX | 52% Loosely correlated | +0.55% | ||
| TMO - BDX | 50% Loosely correlated | -1.33% | ||
| CNMD - BDX | 48% Loosely correlated | +1.05% | ||
| BAX - BDX | 45% Loosely correlated | +1.81% | ||
| RVTY - BDX | 45% Loosely correlated | -1.83% | ||
More | ||||
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with BDX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then BDX could also see price increases.